|Bid||297.81 x 1100|
|Ask||298.58 x 1100|
|Day's range||296.67 - 311.67|
|52-week range||289.00 - 449.38|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||32.47|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||1.36 (0.45%)|
|Ex-dividend date||12 Nov 2021|
|1y target est||398.56|
Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.
Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.
Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.